Revolution Medicines Raises $2.2 B to Fund RAS‑Targeted Oncology Pipeline
Revolution Medicines raises $2.2 billion via equity and convertible notes, funding RAS‑targeted oncology R&D and potential commercialization while maintaining investor confidence.
3 minutes to read